Lysogene Announces Company Presentations at October & November Investor Conferences

Lysogene Announces Company Presentations at October & November Investor Conferences 150 150 Lysogene

Paris, France and Cambridge, MA, US – October 4, 2017 – Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks:

October

  • Chardan Gene Therapy Conference (New York, US)

Date: Tuesday, October 10

Time: 3:45pm Eastern Time

Location: Westin New York Grand Central, Assembly Room

  • Jefferies Gene Editing & Gene Therapy Summit (New York, US)

Date: Thursday, October 12

Time: 2:30pm Eastern Time

Location: Westin New York Grand Central

  • Key Opinion Leader Lunch: Gene Therapy for Patients with Sanfilippo Syndrome Type A (MPS IIIA) (New York, US)

Date: Friday, October 13

Time: 12:00pm – 1:30pm Eastern Time Location: Lotte New York Palace Hotel

Webcast: http://lifesci.rampard.com/20171013/reg.jsp

November

  • Jefferies 2017 London Healthcare Conference (London, UK)

Date: Tuesday, November 14 & Wednesday, November 15 Time: TBD

Location: Waldorf Hilton

About Lysogene

Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.

Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475).

For more information: www.lysogene.com.

Contacts
Media: Investors:
Europe
Annie-Florence Loyer Chris Maggos
NewCap LifeSci Advisors
afloyer@newcap.fr chris@lifesciadvisors.com
+ 33 6 88 20 35 59 +41 79 367 6254
+ 33 1 44 71 00 12
North America
Marion Janic
RooneyPartners
mjanic@rooneyco.com
+ 1 (212) 223-4017

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top